pomalidomide has been researched along with Neutropenia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Einsele, H; Grathwohl, D; Kortüm, KM; Krummenast, F; Leicht, HB; Meckel, K; Nickel, K; Rasche, L; Steinhardt, MJ; Zhou, X | 1 |
| Ahmadi, T; Amin, H; Baldini, L; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Kampfenkel, T; Katodritou, E; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Qiu, Y; Schecter, JM; Sonneveld, P; Symeonidis, A; Terpos, E; Ukropec, J; Vermeulen, J | 1 |
| Delgado, J; Enzmann, H; Gisselbrecht, C; Moreau, A; Pignatti, F; van Hennik, PB; Zienowicz, M | 1 |
| Fuchida, SI; Hino, M; Iida, M; Imada, K; Ishikawa, J; Kamitsuji, Y; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsuda, M; Matsui, T; Matsumura, I; Matsumura-Kimoto, Y; Nakaya, A; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Uchiyama, H; Uoshima, N; Wada, K; Yagi, H; Yokota, I | 1 |
| Dimopoulos, MA; Dytfeld, D; Grosicki, S; Hori, M; Jou, YM; LeBlanc, R; Leleu, X; Moreau, P; Popa McKiver, M; Raab, MS; Rafferty, B; Richardson, PG; Robbins, M; San-Miguel, J; Shelat, SG; Suzuki, K; Takezako, N | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| Cavo, M; Davies, FE; Delforge, M; Dimopoulos, MA; Facon, T; Hansson, M; Leleu, X; Ludwig, H; Mateos, MV; Miguel, JF; Moreau, P; Morgan, GJ; Palumbo, A; Schey, SA; Sonneveld, P; Weisel, K; Zweegman, S | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Hassett, AC; Lentzsch, S; List, A; Mapara, MY; Monaghan, SA; Moscinski, L; Pal, R; Ragni, MV; Roodman, GD; Schafer, P | 1 |
| Lacy, MQ | 1 |
| Brown, KA; Macey, MG; McCarthy, DA; Schey, SA; Streetly, M | 1 |
| Galili, N; Raza, A | 1 |
| Daniel, Y; Gyertson, K; Kazmi, M; Schey, SA; Streetly, MJ; Zeldis, JB | 1 |
4 review(s) available for pomalidomide and Neutropenia
| Article | Year |
|---|---|
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.
Topics: Age Factors; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Humans; Immunologic Factors; Infections; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Quality of Life; Thalidomide; Venous Thromboembolism | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
New immunomodulatory drugs in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neutropenia; Thalidomide; Treatment Outcome | 2011 |
Immunomodulatory drugs in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Apoptosis; Blood Transfusion; Cell Lineage; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Cytokines; Drug Evaluation, Preclinical; Drugs, Investigational; Erythrocyte Transfusion; Erythropoiesis; Female; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; NF-kappa B; Pilot Projects; Thalidomide; Thrombocytopenia; Tumor Necrosis Factor-alpha | 2006 |
6 trial(s) available for pomalidomide and Neutropenia
| Article | Year |
|---|---|
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Progression-Free Survival; Proportional Hazards Models; Thalidomide | 2021 |
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Multiple Myeloma; Neutropenia; Thalidomide | 2021 |
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Immunologic Factors; Infections; Male; Middle Aged; Multiple Myeloma; Neutropenia; Thalidomide | 2018 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64.
Topics: Adult; Aged; Apoptosis; Blood Platelets; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Neutropenia; Neutrophils; Receptors, IgG; Thalidomide | 2006 |
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lymphocyte Subsets; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neutropenia; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
3 other study(ies) available for pomalidomide and Neutropenia
| Article | Year |
|---|---|
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Leukopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pneumonia; Progression-Free Survival; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Treatment Outcome | 2020 |
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Neutropenia; Recurrence; Registries; Retrospective Studies; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2018 |
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-Stimulating Factor; Granulocyte Precursor Cells; Granulocytes; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Myeloid Progenitor Cells; Neutropenia; Neutrophils; Platelet Aggregation; Proto-Oncogene Proteins; Risk Factors; Thalidomide; Trans-Activators; Venous Thromboembolism | 2010 |